ABOUT IJMMS

The International Journal of Medicine and Medical Sciences is published monthly (one volume per year) by Academic Journals.

The International Journal of Medicine and Medical Sciences (IJMMS) provides rapid publication (monthly) of articles in all areas of Medicine and Medical Sciences such as:

Clinical Medicine: Internal Medicine, Surgery, Clinical Cancer Research, Clinical Pharmacology, Dermatology, Gynaecology, Paediatrics, Neurology, Psychiatry, Otorhinolaryngology, Ophthalmology, Dentistry, Tropical Medicine, Biomedical Engineering, Clinical Cardiovascular Research, Clinical Endocrinology, Clinical Pathophysiology, Clinical Immunology and Immunopathology, Clinical Nutritional Research, Geriatrics and Sport Medicine

Basic Medical Sciences: Biochemistry, Molecular Biology, Cellular Biology, Cytology, Genetics, Embryology, Developmental Biology, Radiobiology, Experimental Microbiology, Biophysics, Structural Research, Neurophysiology and Brain Research, Cardiovascular Research, Endocrinology, Physiology, Medical Microbiology

Experimental Medicine: Experimental Cancer Research, Pathophysiology, Immunology, Immunopathology, Nutritional Research, Vitaminology and Ethiology

Preventive Medicine: Congenital Disorders, Mental Disorders, Psychosomatic Diseases, Addictive Diseases, Accidents, Cancer, Cardiovascular Diseases, Metabolic Disorders, Infectious Diseases, Diseases of Bones and Joints, Oral Preventive Medicine, Respiratory Diseases, Methods of Epidemiology and Other Preventive Medicine

Social Medicine: Group Medicine, Social Paediatrics, Medico-Social Problems of the Youth, Medico-Social Problems of the Elderly, Rehabilitation, Human Ecology, Environmental Toxicology, Dietetics, Occupational Medicine, Pharmacology, Ergonomics, Health Education, Public Health and Health Services and Medical Statistics

The Journal welcomes the submission of manuscripts that meet the general criteria of significance and scientific excellence. Papers will be published approximately one month after acceptance. All articles published in IJMMS are peer-reviewed.

Contact

Editorial Office: ijmms@academicjournals.org
Desk: helpdesk@academicjournals.org
Website: http://www.academicjournals.org/journal/IJMMS
Submit manuscript online http://ms.academicjournals.me/
Editors

Dr. J. Ibekwe
Acting Editor-in-chief,
International Journal of Medicine and Medical Sciences Academic Journals
E-mail: ijmms.journals@gmail.com
http://www.academicjournals.org/ijmms

Afrozul Haq
Editor, Laboratory Medicine
Department of Laboratory Medicine
Sheikh Khalifa Medical City
P.O. Box 51900, ABU DHABI
United Arab Emirates
Editorial Board

Chandrashekhar T. Sreeramareddy
Department of Community Medicine,
P O Box No 155, Deep Heights
Manipal College of Medical Sciences,
Pokhara,
Nepal

Sisira Hemananda Siribaddana
259, Temple Road, Thalapathpitiya,
Nugegoda, 10250
Sri Lanka

Dr. Srinivas Koduru
Dept of Clinical Sciences
Collage of Health Sciences
University of Kentucky
Lexington USA

Weiping Zhang
Department of Oral Biology
Indiana University School of Dentistry
1121 West Michigan Street, DS 271
Indianapolis, IN 46202
USA

Lisheng Xu
Ho Sin Hang Engineering Building
Department of Electronic Engineering
The Chinese University of Hong Kong
Shatin, N. T. Hong Kong,
China

Dr. Mustafa Sahin
Department of Endocrinology and Metabolism
Baskent University,
Ankara,
Turkey

Dr. Harshdeep Joshi
Maharishi Markandeshwar
Institute of Medical Sciences and Research
Ambala, (Haryana).
India

Prof. Viroj Wiwanitkit
Wiwanitkit House, Bangkhae,
Bangkok
Thailand 10160

Dr. Santi M. Mandal
Department of Oral Biology
Indiana University School of Dentistry
1121 West Michigan Street, DS 271
Indianapolis, IN 46202
USA

Konstantinos Tziomalos
Department of Clinical Biochemistry
(Vascular Prevention Clinic),
Royal Free Hospital Campus,
University College Medical School, University College
London, London,
United Kingdom

Cyril Chukwudi Dim
Department of Obstetrics & Gynaecology
University of Nigeria Teaching Hospital (UNTH)
P. M. B. 01129, Enugu. 400001,
Nigeria

Mojtaba Salouti
School of Medical and Basic Sciences,
Islamic Azad University- Zanjan,
Iran

Imtiaz Ahmed Wani
Srinagar Kashmir, 190009,
India
**Instructions for Author**

**Electronic submission** of manuscripts is strongly encouraged, provided that the text, tables, and figures are included in a single Microsoft Word file (preferably in Arial font).

The **cover letter** should include the corresponding author’s full address and telephone/fax numbers and should be in an e-mail message sent to the Editor, with the file, whose name should begin with the first author’s surname, as an attachment.

**Article Types**
Three types of manuscripts may be submitted:

**Regular articles**: These should describe new and carefully confirmed findings, and experimental procedures should be given in sufficient detail for others to verify the work. The length of a full paper should be the minimum required to describe and interpret the work clearly.

**Short Communications**: A Short Communication is suitable for recording the results of complete small investigations or giving details of new models or hypotheses, innovative methods, techniques or apparatus. The style of main sections need not conform to that of full-length papers. Short communications are 2 to 4 printed pages (about 6 to 12 manuscript pages) in length.

**Reviews**: Submissions of reviews and perspectives covering topics of current interest are welcome and encouraged. Reviews should be concise and no longer than 4-6 printed pages (about 12 to 18 manuscript pages). Reviews are also peer-reviewed.

**Review Process**
All manuscripts are reviewed by an editor and members of the Editorial Board or qualified outside reviewers. Authors cannot nominate reviewers. Only reviewers randomly selected from our database with specialization in the subject area will be contacted to evaluate the manuscripts. The process will be blind review.

Decisions will be made as rapidly as possible, and the journal strives to return reviewers’ comments to authors as fast as possible. The editorial board will re-review manuscripts that are accepted pending revision. It is the goal of the IMMS to publish manuscripts within weeks after submission.

**Regular articles**
All portions of the manuscript must be typed **double-spaced** and all pages numbered starting from the title page.

The **Title** should be a brief phrase describing the contents of the paper. The Title Page should include the authors’ full names and affiliations, the name of the corresponding author along with phone, fax and E-mail information. Present addresses of authors should appear as a footnote.

The **Abstract** should be informative and completely self-explanatory, briefly present the topic, state the scope of the experiments, indicate significant data, and point out major findings and conclusions. The Abstract should be 100 to 200 words in length. Complete sentences, active verbs, and the third person should be used, and the abstract should be written in the past tense. Standard nomenclature should be used and abbreviations should be avoided. No literature should be cited.

Following the abstract, about 3 to 10 **key words** that will provide indexing references should be listed.

A list of non-standard **Abbreviations** should be added. In general, non-standard abbreviations should be used only when the full term is very long and used often. Each abbreviation should be spelled out and introduced in parentheses the first time it is used in the text. Only recommended SI units should be used. Authors should use the solidus presentation (mg/ml). Standard abbreviations (such as ATP and DNA) need not be defined.

The **Introduction** should provide a clear statement of the problem, the relevant literature on the subject, and the proposed approach or solution. It should be understandable to colleagues from a broad range of scientific disciplines.

**Materials and methods** should be complete enough to allow experiments to be reproduced. However, only truly new procedures should be described in detail; previously published procedures should be cited, and important modifications of published procedures should be mentioned briefly. Capitalize trade names and include the manufacturer’s name and address. Subheadings should be used. Methods in general use need not be described in detail.
**Results** should be presented with clarity and precision. The results should be written in the past tense when describing findings in the authors’ experiments. Previously published findings should be written in the present tense. Results should be explained, but largely without referring to the literature. Discussion, speculation and detailed interpretation of data should not be included in the Results but should be put into the Discussion section.

The **Discussion** should interpret the findings in view of the results obtained in this and in past studies on this topic. State the conclusions in a few sentences at the end of the paper. The Results and Discussion sections can include subheadings, and when appropriate, both sections can be combined.

The **Acknowledgments** of people, grants, funds, etc. should be brief.

**Tables** should be kept to a minimum and be designed to be as simple as possible. Tables are to be typed double-spaced throughout, including headings and footnotes. Each table should be on a separate page, numbered consecutively in Arabic numerals and supplied with a heading and a legend. Tables should be self-explanatory without reference to the text. The details of the methods used in the experiments should preferably be described in the legend instead of in the text. The same data should not be presented in both table and graph form or repeated in the text.

**Figure legends** should be typed in numerical order on a separate sheet. Graphics should be prepared using applications capable of generating high resolution GIF, TIFF, JPEG or Powerpoint before pasting in the Microsoft Word manuscript file. Tables should be prepared in Microsoft Word. Use Arabic numerals to designate figures and upper case letters for their parts (Figure 1). Begin each legend with a title and include sufficient description so that the figure is understandable without reading the text of the manuscript. Information given in legends should not be repeated in the text.

**References:** In the text, a reference identified by means of an author’s name should be followed by the date of the reference in parentheses. When there are more than two authors, only the first author’s name should be mentioned, followed by ‘et al’. In the event that an author cited has had two or more works published during the same year, the reference, both in the text and in the reference list, should be identified by a lower case letter like ‘a’ and ‘b’ after the date to distinguish the works.

**Examples:**

Nishimura (2000), Agindotan et al. (2003), (Kelebeni, 1983), (Usman and Smith, 2001), (Chege, 1998; Stein, 1987a,b; Tijani, 1993,1995), (Kumasi et al., 2001)

References should be listed at the end of the paper in alphabetical order. Articles in preparation or articles submitted for publication, unpublished observations, personal communications, etc. should not be included in the reference list but should only be mentioned in the article text (e.g., A. Kingori, University of Nairobi, Kenya, personal communication). Journal names are abbreviated according to Chemical Abstracts. Authors are fully responsible for the accuracy of the references.

Examples:


Case Studies

Case Studies include original case reports that will deepen the understanding of general medical knowledge.

The Title should be a brief phrase describing the contents of the paper. The Title Page should include the authors' full names and affiliations, the name of the corresponding author along with phone, fax and E-mail information. Present addresses of authors should appear as a footnote.

The Abstract should be informative and completely self-explanatory, briefly present the topic, state the scope of the experiments, indicate significant data, and point out major findings and conclusions. The Abstract should be 100 to 200 words in length. Complete sentences, active verbs, and the third person should be used, and the abstract should be written in the past tense. Standard nomenclature should be used and abbreviations should be avoided. No literature should be cited.

Following the abstract, about 3 to 10 key words that will provide indexing references should be listed.

A list of non-standard Abbreviations should be added. In general, non-standard abbreviations should be used only when the full term is very long and used often. Each abbreviation should be spelled out and introduced in parentheses the first time it is used in the text. Only recommended SI units should be used. Authors should use the solidus presentation (mg/ml).

The Introduction should provide a clear statement of the problem, the relevant literature on the subject, and the proposed approach or solution. It should be understandable to colleagues from a broad range of scientific disciplines.

The presentation of the case study should include the important information regarding the case. This must include the medical history, demographics, symptoms, tests etc. Kindly note that all information that will lead to the identification of the particular patient(s) must be excluded.

The conclusion should highlight the contribution of the study and its relevance in general medical knowledge.

The Acknowledgments of people, grants, funds, etc should be brief.

References: Same as in regular articles

Short Communications

Short Communications are limited to a maximum of two figures and one table. They should present a complete study that is more limited in scope than is found in full-length papers. The items of manuscript preparation listed above apply to Short Communications with the following differences: (1) Abstracts are limited to 100 words; (2) instead of a separate Materials and Methods section, experimental procedures may be incorporated into Figure Legends and Table footnotes; (3) Results and Discussion should be combined into a single section.

Proofs and Reprints: Electronic proofs will be sent (e-mail attachment) to the corresponding author as a PDF file. Page proofs are considered to be the final version of the manuscript. With the exception of typographical or minor clerical errors, no changes will be made in the manuscript at the proof stage. Because IJMMS will be published freely online to attract a wide audience, authors will have free electronic access to the full text (in both HTML and PDF) of the article. Authors can freely download the PDF file from which they can print unlimited copies of their articles.

Copyright: Submission of a manuscript implies: that the work described has not been published before (except in the form of an abstract or as part of a published lecture, or thesis) that it is not under consideration for publication elsewhere; that if and when the Manuscript is accepted for publication, the authors agree to automatic transfer of the copyright to the publisher.
Malignant pleural mesothelioma treated as pulmonary tuberculosis
Aiyekomogbon Joshua Oluwafemi, Chom Nuhu D., Tabari Abdulkadir Musa,
Igashi Joseph Bako, Delia Zira Ibrahim and Adamu Abdullahi
Case Report

Malignant pleural mesothelioma treated as pulmonary tuberculosis

Aiyekomogbon Joshua Oluwafemi¹,2*, Chom Nuhu D.³, Tabari Abdulkadir Musa⁴, Igashi Joseph Bako³, Delia Zira Ibrahim⁵ and Adamu Abdullahi⁶

¹Departments of Radiology, Federal Staff Medical Centre Abuja, Nigeria.
²Ahmadu Bello University Teaching Hospital, Zaria, Nigeria.
³Department of Radiology, Ahmadu Bello University/Ahmadu Bello University Teaching Hospital, Zaria, Nigeria.
⁴Department of Radiology, Aminu Kano Teaching Hospital, Kano/Visiting Consultant ABUTH, Zaria, Nigeria.
⁵Cardiothoracic Unit, Department of Surgery, Ahmadu Bello University Teaching Hospital, Zaria, Nigeria.
⁶Department of Radio-Oncology/Radiotherapy, Ahmadu Bello University Teaching Hospital, Zaria, Nigeria.

Received 1 November, 2015; Accepted 14 December, 2015

A 45 year old man with malignant pleural mesothelioma had symptoms of prolonged cough, haemoptysis, breathlessness, weight loss and low grade persistent fever. The high prevalence of pulmonary tuberculosis in this environment, coupled with paucity of radiologists in rural areas to competently review his chest radiograph, resulted in making the wrong diagnosis of pulmonary tuberculosis (PTB) as against malignant pleural mesothelioma. He was also wrongly treated for PTB for a period of nine months before referral to a Teaching Hospital. The correct diagnosis was made in a university teaching hospital where adequate specialized manpower was available. Distant metastasis to the liver was already observed at presentation. He was treated with six courses of chemotherapy (Pezlitaxel and Cisplastin) and he did well before he was lost to follow-up.

Key words: Malignant pleural mesothelioma, PTB, liver metastasis.

INTRODUCTION

Mesothelioma (or, more precisely malignant mesothelioma) is a rare form of cancer that develops from transformed cells originating in the mesothelium, the protective lining that covers many of the internal organs of the body. In the lungs, it is usually caused by exposure to asbestos (CancerHelp UK, 2010; Ashrafian et al., 2005). The most common anatomical site for the development of mesothelioma is the pleura (visceral and parietal pleura), but can also arise in the peritoneum, and the pericardium, or the tunica vaginalis (CancerHelp UK, 2010). There seems to be no association between mesothelioma and tobacco smoking, but smoking greatly increases the risk of developing other asbestos-induced cancers (Stahel et al., 2010).

Malignant mesothelioma of the lungs poses an extraordinary challenge to the Pulmonologists, Cardio-
thoracic Surgeons, and Radiologists because radiological and clinical findings may be indistinguishable from closely related differential diagnosis like pulmonary tuberculosis (PTB) (Stahel et al., 2010; Bianchi and Bianchi, 2007). Late diagnosis is therefore common, as it was in the index case.

This case is reported to reiterate the fact that malignant pleural mesothelioma and pulmonary tuberculosis share common clinical features and high index of suspicion is needed to avoid diagnostic pitfall.

CASE REPORT

A 45 year old male primary school teacher was referred from Federal Medical Center (FMC) Azare to Ahmadu Bello University Teaching Hospital (ABUTH) Zaria on account of poor response to nine month course of anti-TB drugs. He presented to the FMC eleven months earlier with a five month history of cough, breathlessness, low-grade fever and weight loss. A chest x-ray done suggested features of pulmonary tuberculosis (PTB) which led to commencement of anti-TB drugs. Following a nine month course of the anti-TB, deterioration of the clinical state of the patient as well as worsening of the radiological features on chest x-ray was noted. He was not a known hypertensive or diabetic patient. He neither smoked cigarette nor drank alcohol and has never worked in an asbestos factory. He denied history of being a passive smoker prior to the onset of his illness. Clinical examination revealed an ill-looking middle aged man, asthenic, with puffy red eyes and facial swelling. Massively distended neck veins as well as veins of the anterior chest wall were noted. There was right supraventricular and left axillary lymphadenopathy. The nodes were averagely 1 cm in dimension, multiple, discrete, firm and freely mobile. No tenderness was elicited over them and there was no finger clubbing. Chest examination revealed diminished right chest expansion associated with dull percussion note and decreased air entry in the upper, middle and lower zones of the right lung. The left lung field was clinically clear but the trachea was mildly buckled to the left. No remarkable findings were noted in the remaining systems. Investigations requested included Contrast-enhanced chest CT scan and CT-guided biopsy of the right pleural mass, abdominal ultrasound scan and retroviral screening.

The chest scanogram revealed a homogenous opacity of soft tissue density in the right lung apex, extending through the right hilum to the lower zone, obliterating the ipsilateral cardiac border (Figure 1). The right main bronchus was compressed by the mass. There was right pleural fluid collection and non-homogenous opacities with background streakiness and nodularity in the remaining right lung fields. The left lung field and the rib cage were preserved. Computed tomographic scan (Figure 2 to 4) revealed a pleural base lobulated isodense mass (HU = 40) making an obtuse angle with the chest wall. It extended to the adjacent lung parenchyma and hilum, encircling and narrowing the right main bronchus. The distal trachea was bowed and displaced to the contralateral side. Associated nodular right pleural thickening and isodense lesion of fluid density in keeping with pleural effusion were also noted. Abdominal ultrasound scan revealed oval-shaped hypoechoic masses with uniform margins in the right lobe of the liver. The largest measures $3.3 \times 2.5$ cm in dimension (Figure 5). A radiological diagnosis of malignant mesothelioma of the right lung with liver metastasis was made.

CT-guided biopsy of the mass lesion confirmed the diagnosis. He had six courses of chemotherapy at three weeks interval (Peciltaxel and Cisplastin) with marked clinical improvement, evidenced by cessation/reduced frequency of cough and haemoptysis coupled, with significant weight gain. He was lost to follow-up after the chemotherapy presumably due to financial constraints. Follow-up radiological assessment was not possible due to the aforementioned reason.

DISCUSSION

Mesothelioma is a rare type of cancer that primarily affects the lining of the lungs, but can also affect the heart, abdomen and other organs (CancerHelp UK, 2010). Mesotheliomas are classified into epithelial, mixed, sarcomatoid and undifferentiated types, based on conventional histological examination. The classification provides important prognostic information. Furthermore, differential diagnosis is directly related to histological type (Corson, 1997). The Epithelialoid form is the commonest type of the mesothelioma, which is the type diagnosed in the index case. Although reported incidence rates have increased in the past 20 years, mesothelioma is still a relatively rare cancer. The incidence rate varies from one country to another, from a low rate of less than 1 per 1,000,000 in Tunisia and Morocco, to the highest rate in Britain, Australia and Belgium, 30 per 1,000,000 per year (Bianchi and Bianchi, 2007). The incidence of malignant mesothelioma of the lungs currently ranges from about 7 to 40 per 1,000,000 in industrialized Western Nations, depending on the amount of asbestos exposure during the past several decades (Robinson and Lake, 2005). It occurs more often in men than in women and risk increases with age (Bianchi and Bianchi, 2007; Robinson and Lake, 2005). The index case was a 45 year old man.

Symptoms and signs of malignant mesothelioma of the lungs may not appear until 20 to 50 years (or more) after exposure to asbestos (Robinson and Lake, 2005). Shortness of breath, cough, haemoptysis and chest pain due to pleural effusion are the symptoms of pleural mesothelioma. Some may present with weight loss and
Figure 1. A scanogram of the chest in a CT study showing homogenous opacity of soft tissue density with spiculated margins in the right hemithorax, extending through the right hilum to the right lower zone (white arrow). The distal trachea and the right main bronchus are compressed. Right pleural effusion and non-homogenous opacity with background streakiness are also noted in the remaining right lung parenchyma. (ORIGINAL IMAGE).

Figure 2. Non-contrast chest CT at the level of the hilum (mediastinal window) showing a pleural base lobulated isodense soft tissue mass (HU=52) in the right anterior mediastinum, extending posteriorly and making an obtuse angle with the posterior chest wall. There is encroachment of the right lung parenchyma and hilum; with encasement and narrowing of the right main bronchus (white arrow) (original image).
low grade fever. If the cancer has caused obstructive symptoms or has spread beyond the mesothelium to other parts of the body, pain, dysphagia, odynophagia, or swelling of the neck or face may be experienced. Most of the enumerated symptoms, though non-specific, were found in this patient. These symptoms coupled with chest x-ray and CT findings may make one to suspect the diagnosis but must be confirmed histologically as it was in the index case. This confirmation is necessary as malignant pleural mesothelioma simulates a number of other disease conditions other than PTB; these include: adenocarcinoma of the lung, non-small cell lung cancers, oat cell (small cell) lung cancer, drug-induced pulmonary reactions, actinomycosis, benign mesothelial hyperplasia, lymphoma, carcinoma metastatic to the pleural from Breast, ovarian, renal and colonic adenocarcinomas (Zandwijk et al., 2013; Husain et al., 2013).

Different types of mesothelioma have been described, based on the site of origin. These includes: pleural mesothelioma, peritoneal mesothelioma, pericardial mesothelioma and tunica vaginalis mesothelioma which almost always affect the testicles (CancerHelp UK, 2010). History of asbestos exposure exists in most cases. However, mesothelioma has been reported in some individuals without any known exposure to asbestos as it was in the index case (CancerHelp UK, 2010).

The non-specificity of the symptoms, signs and radiological features in patients with mesotheliomas has further complicated the issue of prognosis as most patients are only diagnosed at advanced stage. Generally, the prognosis for malignant mesothelioma remains disappointing, although there have been some modest improvement in prognosis from newer chemotherapies and multimodality treatment (Borasio et al., 2008). Treatment of malignant mesothelioma at earlier stages has a better prognosis, but cures are exceedingly rare (Borasio et al., 2008). Histological subtype, patient’s age and health status are important
prognostic factors. The epitheloid histologic type responds better to treatment and has a survival advantage over sarcomatoid histologic type (Haber and Haber, 2011).

Diagnosing mesothelioma is often difficult, because the symptoms are similar to those of a number of other conditions (Stahel et al., 2010; Haber and Haber, 2011), as noted in the index case. Chest x-ray is helpful and may reveal pleural thickening commonly seen after asbestos exposure. The radiographic appearance is of a well defined lobulated mass with a pleural base; the mass may be small or occupy most of the hemithorax. On CT, large tumors may show areas of differential enhancement, and also areas of low attenuation due to necrosis (Micheal and Simon, 2003). The extent of malignant mesothelioma is best assessed by CT or magnetic resonance imaging (MRI), but biopsy is generally needed to confirm its diagnosis (Stahel et al., 2010). This patient had a CT-guided biopsy which confirmed the diagnosis. Surgery, radiation therapy and chemotherapy are the treatment protocols available for mesothelioma. Surgery, by itself, has proved disappointing. In one large series, the median survival with surgery (including extrapleural pneumonectomy) was only 11.7 months (Borasio et al., 2008). However, the research indicated varied success when used in combination with radiotherapy and chemotherapy.

Chemotherapy is the only singular treatment protocol that has been proven to improve survival in randomized and controlled trials. The combination of cisplatin and peclitaxel (Pemetrexed) has been found useful,
particularly with supplementation with folate and vitamin B₁₂ (Vogelzang et al., 2003). The index case had this combination therapy and his response was satisfactory before he was lost to follow-up. Treatment regimens involving immunotherapy have yielded variable results (Gregoire, 2010). Trials involving interferon alpha have proved encouraging with 20% of patients experiencing a greater than 50% reduction in tumour mass with minimal side effects (Gregoire, 2010). This was not contemplated due to the cost implication as this patient could not even commence chemotherapy until after 2 months, which is much cheaper than immunotherapy.

**Conclusion**

A case of malignant Pleural Mesothelioma with liver metastasis wrongly managed for pulmonary tuberculosis has been presented. The case history, radiological findings, treatment options and literature have been reviewed. It emphasizes the role of imaging and high index of suspicion in the management of patients with malignant pleural mesothelioma. The need for adequate specialized manpower in every major hospital in Nigeria cannot be overemphasized, as that will enhance the quality of patient care and avert the diagnostic pitfalls initially encountered in the index case. Also, microbiological assessment of the sputum (Sputum AFB) will go a long way to establish a diagnosis of Tuberculosis and this must be done in all suspected cases of PTB before commencing treatment.

**Conflict of interests**

Authors have not declared any conflict of interest

**ACKNOWLEDGEMENT**

Dr. Ahmed Sa’ad of Department of Pathology, Ahmadu
Bello University is greatly acknowledged and appreciated for his immense contribution.

REFERENCES


